



February 17, 2021

Dear Rett Syndrome Community,

As you may have seen, Taysha recently provided an update about TSHA-102, our investigational gene therapy candidate for the treatment of Rett syndrome. We plan to work closely with the U.S. Food and Drug Administration (FDA) and regulatory agencies outside of the United States to progress TSHA-102 towards an Investigational New Drug (IND) application and a Clinical Trial Application (CTA) respectively, and we expect to submit these applications during the second half of this year. This application process is required before a clinical trial can begin. If the IND and CTA applications are accepted, we will have permission to start a clinical trial in patients and plan to share more information about the clinical trial at that time.

Some gene therapies try to replace or repair a missing or dysfunctional gene that causes disease. In the case of TSHA-102, our goal is to deliver a functional, shortened version of the MECP2 gene to the brain with the hope of providing cells with the genetic 'instructions' they need to function properly. The functional gene is packaged with our unique technology to automatically control the level of MECP2 protein expression. In Rett syndrome, too much protein expression may be harmful and too little may not produce a therapeutic effect. The American Society of Gene & Cell Therapy (ASGCT) has educational information on gene therapy located [here](#).

"We remain committed to understanding the unique challenges the Rett syndrome community faces. Our team is truly embracing an integrated approach to get new and life-changing medicines in the hands of physicians treating those diagnosed with this condition."

- RA Session II, Founder, President & CEO, Taysha Gene Therapies

We are encouraged by the strength of the Rett syndrome patient community and look forward to updating you through our advocacy partners as information becomes available. Working together, we can continue to deepen our understanding of this condition.

Warm regards,

The Taysha Team

This communication contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Forward-looking statements are based on Taysha's current expectations and are subject to various risks and uncertainties that could cause actual results to differ materially and adversely, including those described in our filings with the Securities and Exchange Commission, which is available at www.sec.gov. These forward-looking statements speak only as of the date hereof, and we disclaim any obligation to update these statements except as may be required by law.